Secondary Hyperparathyroidism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Secondary Hyperparathyroidism - Pipeline Review, H2 2016

Secondary Hyperparathyroidism - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Secondary Hyperparathyroidism - Pipeline Review, H2 2016
Published Jul 13, 2016
57 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Secondary Hyperparathyroidism - Pipeline Review, H2 2016, provides an overview of the Secondary Hyperparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
- The report reviews pipeline therapeutics for Secondary Hyperparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Secondary Hyperparathyroidism therapeutics and enlists all their major and minor projects
- The report assesses Secondary Hyperparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8282IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Secondary Hyperparathyroidism Overview71
Therapeutics Development81
  Pipeline Products for Secondary Hyperparathyroidism Overview81
Secondary Hyperparathyroidism Therapeutics under Development by Companies91
Secondary Hyperparathyroidism Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Secondary Hyperparathyroidism Products under Development by Companies131
Secondary Hyperparathyroidism Companies Involved in Therapeutics Development144
  Amgen Inc.141
  Deltanoid Pharmaceuticals Inc.151
  Mitsubishi Tanabe Pharma Corporation161
  OPKO Health, Inc.171
Secondary Hyperparathyroidism Therapeutics Assessment189
  Assessment by Monotherapy Products181
  Assessment by Target192
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Drug Profiles2716
  Calcimimetic-18 Drug Profile271
  CTA-091 Drug Profile281
  CTAP-201 Drug Profile291
  DP-001 Drug Profile301
  etelcalcetide hydrochloride Drug Profile315
  lunacalcipol Drug Profile362
  MT-4580 Drug Profile382
  VS-105 Drug Profile401
  VS-110 Drug Profile411
  VS-411 Drug Profile421
Secondary Hyperparathyroidism Dormant Projects431
Secondary Hyperparathyroidism Discontinued Products441
Secondary Hyperparathyroidism Product Development Milestones4511
  Featured News &Press Releases451
    May 24, 2016: ONO Announces Results from Phase 1/2 and Phase 3 Clinical Studies of Etelcalcetide Hydrochloride (ONO-5163) in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ERA-EDTA Congress451
    Jan 26, 2016: Investigational Agent Shows Promise for SHPT in Hemodialysis Patients451
    Jan 14, 2016: ONO Submits Manufacturing and Marketing Approval Application in Japan for Etelcalcetide Hydrochloride (ONO-5163), a Calcimimetic Agent, for Secondary Hyperparathyroidism in Patients on Hemodialysis461
    Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan461
    Nov 07, 2015: Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis471
    Nov 06, 2015: FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide481
    Sep 02, 2015: Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency491
    Aug 25, 2015: Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide491
    May 29, 2015: Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease501
    Feb 25, 2015: Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis511
    Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis521
    Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan531
    Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis531
    Jan 06, 2012: KAI Pharmaceuticals Announces Initiation Of Second Phase II Study Of KAI-4169541
    Nov 14, 2011: KAI Announces Results from Phase II study of ONO-5163/KAI-4169, Calcium Sensing Receptor Agonist542
Appendix562
  Methodology561
  Coverage561
  Secondary Research561
  Primary Research561
  Expert Panel Validation561
  Contact Us561
  Disclaimer571

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Secondary Hyperparathyroidism - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Secondary-Hyperparathyroidism-Pipeline-Review-H2-2016-2088-16177>
  
APA:
Global Markets Direct - Market Research. (2016). Secondary Hyperparathyroidism - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Secondary-Hyperparathyroidism-Pipeline-Review-H2-2016-2088-16177>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.